Dry Days Health urinary incontinence clinic goes in-network with BlueCross BlueShield Maryland
Specialist bladder health care now available to more than a million women in the state
Dry Days Health, a virtual clinic for women living with urinary incontinence, is now in-network with CareFirst BlueCross BlueShield Maryland, expanding access to specialist-led bladder health care for more than a million women in the state.
Pelvic health company Amara Therapeutics originally launched Dry Days Health in 2025 to support one of the most common yet under-treated conditions in women’s health, estimated to affect up to 1 in 3 women globally.
The company, which operates from Baltimore, Maryland, and Galway, Ireland, created the clinic to address longstanding barriers that prevent many women from receiving appropriate treatment. It offers virtual appointments with licensed clinicians, providing personalised treatment plans delivered remotely.
Amara Therapeutics CEO Brendan Staunton said: “Urinary incontinence affects millions of women, yet far too many never receive timely, specialist-led care due to access barriers, stigma, long wait times, and fragmented treatment pathways.
”By combining virtual specialist care with our digital-first treatment pathway, we are making it easier for women to access insurance-covered care from home - while helping health systems identify and support patients earlier.”
More broadly, Amara Therapeutics develops digital therapeutics and virtual care solutions for pelvic and bladder health conditions, including urinary incontinence and overactive bladder. The company says Dry Days Health is part of its broader mission to redesign how women access and sustain treatment for these conditions.
”This milestone represents another step forward in our mission to modernize women’s pelvic health care and build a scalable, integrated pathway for urinary incontinence treatment in the United States,” continued Brendan.
The announcement on Dry Days Health coincides with growing investor and payer interest in urinary incontinence and pelvic health. Earlier this month, UroMems raised $60m to advance its smart implant for stress urinary incontinence, BlueWind Medical raised $47.8m to expand commercialisation of its Revi implant for urge urinary incontinence, and Australia’s NinaMED launched with $13.75m for overactive bladder therapy. Together, they demonstrate increased recognition that urinary incontinence is a major chronic health category with significant unmet need, specialist shortages and long-term quality-of-life impacts.